Clinical Report: Could Stool Enzyme Activity Signal IBD?

Overview

A novel stool assay measuring granzyme A (GzmA) enzyme activity shows promise as a noninvasive biomarker for monitoring inflammatory bowel disease (IBD). This assay may provide insights into T cell-associated inflammation, potentially complementing existing diagnostic methods.

Background

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is characterized by chronic intestinal inflammation. Current diagnostic approaches rely heavily on invasive procedures like endoscopy and histopathology, alongside biomarkers such as fecal calprotectin. The development of noninvasive biomarkers like GzmA activity could enhance monitoring and management of IBD, particularly in cases where traditional markers do not align with clinical findings.

Data Highlights

Key Findings

• The GzmA assay detects enzyme activity rather than protein concentration.
• Increased GzmA levels were observed in inflamed intestinal tissue.
• CD8-positive T cells were identified as a source of active GzmA.
• GzmA activity correlates with the induction of interleukin 8 (IL-8), indicating a role in pro-inflammatory signaling.
• The assay may help distinguish IBD from healthy controls.

Clinical Implications

The GzmA stool assay could provide a valuable tool for monitoring IBD, particularly in cases where symptoms and existing biomarkers do not correlate. However, further validation is necessary before clinical implementation, as it does not replace the need for histologic evaluation.

Conclusion

The development of a stool assay for granzyme A activity represents a promising advancement in the noninvasive monitoring of inflammatory bowel disease, warranting further research to establish its clinical utility.

References

1. A chemiluminescence assay targeting granzyme A activity for monitoring inflammatory bowel disease, Nature Biomedical Engineering, 2025 -- Title
2. Increased Risk of Adverse Reactions to Foodborne Toxins and Medications in Patients with Inflammatory Bowel Disease: A Comprehensive Review, Archives of Toxicology, 2024 -- Title
3. Endoscopic Brush Sample Analysis Reveals Mucosal Dysbiosis in Patients with Inflammatory Bowel Disease, Journal of Gastroenterology, 2017 -- Title
4. Association of Medium-Chain and Long-Chain Fatty Acids with Diarrhea-Predominant Irritable Bowel Syndrome Identified through DESI-MSI Analysis, Journal of Gastroenterology, 2023 -- Title
5. ACG Clinical Guideline: Management of Crohn's Disease, Official journal of the American College of Gastroenterology, 2025 -- Title
6. Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis, Inflammatory Bowel Diseases, 2025 -- Title
7. Efficacy of STW 5 in a Rat Model of Colitis Induced by Dextran Sulfate Sodium
8. Official journal of the American College of Gastroenterology | ACG
9. Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis | Inflammatory Bowel Diseases | Oxford Academic
10. A chemiluminescence assay targeting granzyme A activity for monitoring inflammatory bowel disease | Nature Biomedical Engineering